Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Multiple Sclerosis

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/135245859700300610PMID 9493643
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b

  1996cited by this paper
• Regression analysis for correlated data.

  1993cited by this paper
• An overview of methods for the analysis of longitudinal data.

  1992cited by this paper

• Chapter 2 . 1 Reduced biological activity of recombinant IFN-β and treatment response IFN-β bioactivity measurement in MS : feasibility for routine clinical practice

  2014cites this paper
• Interferon-β bioactivity measurement in multiple sclerosis: feasibility for routine clinical practice

  2009cites this paper
• Lack of interferon‐beta bioactivity is associated with the occurrence of relapses in multiple sclerosis

  2009cites this paper
• Interferon-β1b in the treatment of multiple sclerosis

  2005cites this paper
• Placebo-controlled multicentre randomised trial of interferon (cid:1) -1b in treatment of secondary progressive multiple sclerosis

  2005cites this paper
• Long‐term persisting interferon beta‐1b neutralizing antibodies after discontinuation of treatment

  2004cites this paper
• [Certain problems of therapy with beta-interferon preparations].

  2003cites this paper
• Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis

  2003cites this paper
• Neutralising antibodies to interferon beta during the treatment of multiple sclerosis

  2002cites this paper
• Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

  2002cites this paper
• Chapter 11 Multiple Sclerosis

  2001cites this paper
• L. DurelliA. OggeroE. VerdunP. BarberoA. PipieriG. IsoardoA. Ricci M. ClericoG. BradacB. BergamascoM. Bergui

  2001cites this paper
• Interferon-beta dose and efficacy: the OPTIMS study.

  2001cites this paper
• Interferon-β dose and efficacy: the OPTIMS study

  2001cites this paper
• Interferon in relapsing-remitting multiple sclerosis.

  2001cites this paper
• Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.

  2001cites this paper
• Neutralizing and binding anti‐interferon‐β (IFN‐β) antibodies. A comparison between IFN‐β‐1a and IFN‐β‐1b treatment in multiple sclerosis

  2000cites this paper
• Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?

  2000cites this paper
• Interferon β‐1b in Multiple Sclerosis

  2000cites this paper
• Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.

  1999cites this paper
• Evaluation of binding and neutralizing antibodies to interferon beta-1b in multiple sclerosis patients receiving treatment : development and validation of a new Elisa compared to existing antibody detection techniques and the search for a clinical correlate

  1999cites this paper
• Immunmodulatorische Stufentherapie der multiplen Sklerose

  1999cites this paper
• Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders.

  1999cites this paper
• Glatiramer Acetate or Interferon-β for Multiple Sclerosis?

  1999cites this paper
• Neutralising Antibodies to Interferon-β in the Treatment of Multiple Sclerosis

  1999cites this paper
• Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis

  1998cites this paper
• Antibodies to beta-interferons in multiple sclerosis

  1998cites this paper
• Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

  1998cites this paper
• Multiple Sclerosis Clinical Trials: Old and New Challenges

  1998cites this paper
• Interferon beta therapy for multiple sclerosis.

  1998cites this paper
• Statistical Methods for Evaluating Multiple Sclerosis Therapies

  1998cites this paper
• Update in clinical trials and immunological monitoring in multiple sclerosis

  1998cites this paper